“Blinatumomab is excellent at eradicating MRD in a [patient with] MRD-positive [disease], regardless of which ALL it is, ...

Leah Katz, MD, MPH, discusses long-term IDEA trial data on omitting radiation and why endocrine therapy tolerance matters in ...

Matulonis, MD, broke down the trial design, backbone regimen, and preclinical rationale that she believes made KEYNOTE-B96 a ...

You're absolutely correct. The more recent approvals have certainly been for mirvetuximab [soravtansine] for our patients ...

The faculty consider how they would answer a patient who is 5 years out from a single infusion in sustained MRD-negative ...

Erik Bengtsen, MD, described what sets psycho-oncology apart and how clinicians can open conversations on body image and ...

Panelists discuss which patients at first relapse make them think of CAR T-cell therapy and which make them pause, including ...

The new guidelines include 10 recommendations spanning extended molecular testing, JAK inhibitor use, anemia management, and ...

Ralph V. Boccia, MD, FACP, explained how community practices can build the workflow and capacity to deliver bispecific step-up dosing in an outpatient setting.

Erik Bengtsen, MD, shares a key depression screening question and explains when oncologists can start a low-dose ...

As radiotherapy becomes more strategically integrated around CAR T-cell therapy in multiple myeloma, clinicians face a choice ...

In a phase 1 trial of patients with platinum-sensitive high-grade ovarian cancer, a personalized neoantigen vaccine plus ...